Abstract # 2945 Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy

Presenter: Musmacher, Jeffrey

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

Post-implant dosimetric evaluation has become an increasingly important means of measuring and documenting the quality of permanent prostate brachytherapy implants. A new radioisotope, Cesium-131 (Cs-131), has recently been added to the sources - Iodine-125 and Palladium-103 - available for prostate brachytherapy. The physical properties of Cs-131, namely energy (30 keV) and half-life (10 days) differ somewhat from other available sources. The dosimetric implications of these differences in physical properties among all available isotopes have yet to be fully characterized. This study represents an attempt to quantify dosimetric outcomes using post-plan dosimetry data following Cs-131 and Palladium-103 (Pd-103) following therapeutic implantation.